Back to today’s briefing

Story perspectives

Revolutionary Blood Test Detects Early Cancer Residual Disease

1/22/2025

28 4

Summary

Story summary

Datar Cancer Genetics has unveiled the groundbreaking Target-MRD blood test, designed to monitor molecular residual disease in solid organ cancers. By harnessing cutting-edge next-generation sequencing and droplet digital PCR, this innovative test empowers oncologists to detect minimal residual disease early, paving the way for personalized and effective cancer management.

1 of 1

Story summary

Datar Cancer Genetics has unveiled the groundbreaking Target-MRD blood test, designed to monitor molecular residual disease in solid organ cancers. By harnessing cutting-edge next-generation sequencing and droplet digital PCR, this innovative test empowers oncologists to detect minimal residual disease early, paving the way for personalized and effective cancer management.